

**TABLE 4 Accuracy of predict AUC by one-point and two-point sampling strategy in patients with body weight  $\leq 23$  kg**

UPN	Sex	Age (years)	Disease	Body weight (kg)	Bu dose (mg/kg)	LSS*	C <sub>3</sub> (ng/mL)	C <sub>6</sub> (ng/mL)	Predicted AUC ( $\mu\text{mol}\cdot\text{min/L}$ )	Actual AUC ( $\mu\text{mol}\cdot\text{min/L}$ )	Error (%)
1	Female	6.3	CAEBV	18.0	0.7	One-point	–	190	769	618	+24.4
						Two-point	396		657		+6.3
2	Male	6.2	WAS	19.2	0.6	One-point	–	177	729	554	+31.7
						Two-point	296		559		+0.8
3	Female	4.6	MDS	12.0	1.0	One-point	–	245	936	944	–0.9
						Two-point	666		955		+1.1
4	Male	0.9	IFN- $\gamma$ R1 deficiency	6.2	0.7	One-point	–	130	587	579	+1.3
						Two-point	394		560		–3.2
5	Male	2.0	MPS	16.3	0.9	One-point	–	412	1443	1349	+7.0
					Test does	Two-point	833		1350		+0.1
					0.9	One-point	–	375	1276	1347	–5.3
					First does	Two-point	750		1198		–11.1
6	Female	8.3	HSA	19.5	0.9	One-point	–	299	1100	942	+16.7
						Two-point	556		963		+2.2
7	Male	1.0	MS	8.8	0.8	One-point	–	266	1000	867	+15.3
					Test dose	Two-point	400		781		–9.9
					1.1	One-point	–	261	984	1110	–11.3
					First does	Two-point	785		1073		–3.4

\*Two-points sampling strategy, predicted  $\text{AUC}_{0-\infty} = 0.778 C_3 + 1.589 C_6 + 47.1$ ; One-point sampling strategy, predicted  $\text{AUC}_{0-\infty} = 3.036 C_6 + 192.0$

Abbreviations: Bu, busulfan; LSS, limited sampling strategy; AUC, area under the concentration-time curve;  $C_n$ , busulfan plasma concentration after the start of infusion; CAEBV, chronic active Epstein-Barr virus infection; WAS, Wiskott-Aldrich syndrome; MDS, myelodysplastic syndrome; IFN- $\gamma$ R1, interferon gamma receptor 1; MPS, mucopolysaccharidosis; HSA, hereditary sideroblastic anemia; MS, myeloid sarcoma